To find out more about current Ear, Nose and Throat studies you can view a list of studies on the NIHR Clinical Research Network Portfolio Database
The NIHR Clinical Research Network Cancer has been enormously successful in integrating clinical research into NHS clinical service provision, and both developing and delivering a large practice changing portfolio of clinical trials.
As the most integrated clinical research system in the world, the NIHR supports research studies in Ear, Nose and Throat through our funding programmes, training and supporting health researchers and providing world-class research facilities. We also support dialogue between the life sciences industry and charities to benefit all, and facilitate the involvement of patients and the public to make research more effective.
Last year (2017/2018) the NIHR supported 69 Ear Nose and Throat studies. The NIHR supported these studies through our funding programmes and our research schools and units. We also support Ear Nose and Throat research through our research infrastructure and our training and career development awards for researchers.
The research supported by the Ear Nose and Throat specialty includes studies involving Otology, Neurotology / Skull Base Surgery, Rhinology, Head and Neck including Thyroid and Parathyroid Surgery, and Larynology. Research interests also cover a broad spectrum of conditions, including otitis media, auditory neuroscience, head and neck cancer, rhinology, paediatric ENT and skull base surgery. We provide help and guidance for portfolio inclusion, encourage patient and public involvement, provide links into other ENT Networks, work with the life sciences industry and raise the profile of ENT research.
Multiple-dose clinical safety trial of OTO-104 in Ménière’s disease
The partnership with the NIHR CRN ENT Specialty was essential in the successful completion of a one-year, multiple-dose clinical safety trial of OTO-104 in Ménière’s disease that was conducted in the UK. Based on this success, CRN ENT has extended its collaboration as part of an ongoing Phase 3 clinical trial (AVERTS-2) designed to assess the effectiveness of OTO-104 in Ménière’s disease patients that is being conducted in multiple European countries.
Otitis media with effusion, also known as glue ear, is a very common condition, especially in young children. Whilst we know that glue ear usually gets better by itself, in thousands of children each year it can cause hearing loss, which can lead to further problems such as difficulty with learning and speech development. If hearing loss lasts longer than three months children are often offered a grommet operation and sometimes a hearing aid. Some research studies have found that taking a prescribed steroid medication for a short period seems to result in glue ear getting better in some children. However, the studies that have been done so far have been small, have mostly not measured the effect on hearing and learning, and have not measured how long any effects last. If treatment with an oral steroid does improve hearing then it is likely that some children can avoid having an operation or needing to wear a hearing aid. The OSTRICH study aims to provide more definite measurements, recruiting 380 children aged between two to eight years who have glue ear for at least three months.
You can find out more about Ear, Nose and Throat studies in your area through the UK Clinical Trials Gateway.